Trial Profile
A retrospective,cohort analysis to assess effectiveness of Sunitinib in patients with advanced Pancreatic neuroendocrine tumors
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Mar 2017
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 29 Mar 2017 New trial record